Article
Public, Environmental & Occupational Health
Rebecca Persson, Myriam Cordey, Maria Paris, Susan Jick
Summary: This study compared the incidence rates of adverse events in patients receiving apremilast with those receiving other systemic treatments for psoriasis or psoriatic arthritis. The results showed that there were no new safety signals identified in the apremilast-exposed cohort. The incidence rates of adverse events were comparable between the apremilast and non-apremilast cohorts, indicating that the long-term safety of apremilast in real-world settings is similar to that reported in clinical trials.
Article
Dermatology
Philip J. Mease, Guelen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, Andrea Flower, Hernan Picard, Linda Stein Gold
Summary: This study conducted a pooled analysis of apremilast data from 15 clinical studies with open-label extension phases, finding that the incidence of serious adverse events and adverse events of special interest was low despite long-term use of apremilast in all patients. This further establishes apremilast as a safe oral option for long-term use across indications with a favorable benefit-risk profile.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2023)
Article
Dermatology
Akimichi Morita, Yukie Yamaguchi, Chiharu Tateishi, Kyoko Ikumi, Aya Yamamoto, Haruna Nishihara, Daisuke Hayashi, Yukihiko Watanabe, Yuko Watanabe, Ayano Maruyama, Koji Masuda, Daisuke Tsuruta, Norito Katoh
Summary: This study compared the efficacy and safety of phototherapy as monotherapy and the combination of phototherapy and apremilast in patients with psoriasis vulgaris. The combination therapy showed significantly better efficacy at 4 and 8 weeks, but had more frequent adverse events. The findings suggest that an 8-week combination regimen may be inadequate and longer treatment periods may be necessary for improvements in subjective assessment of psoriasis.
JOURNAL OF DERMATOLOGY
(2022)
Review
Dermatology
Yara E. Aljefri, Abdullah A. Ghaddaf, Tala A. Alkhunani, Taif A. Alkhamisi, Rana A. Alahmadi, Awadh M. Alamri, Ali A. Alraddadi
Summary: This study evaluated the efficacy and safety of apremilast monotherapy for moderate-to-severe plaque psoriasis. The results indicated that apremilast was more effective than placebo in achieving PASI-75, with higher rates of adverse events observed in the 30 mg BID group.
DERMATOLOGIC THERAPY
(2022)
Review
Biochemistry & Molecular Biology
Andrea Picchianti-Diamanti, Francesca Romana Spinelli, Maria Manuela Rosado, Fabrizio Conti, Bruno Lagana
Summary: Phosphodiesterases (PDEs) are a diverse family of enzymes that regulate intracellular second messengers, with PDE4 being the most studied isoenzyme known for its role in down-regulating inflammatory responses. Inhibition of PDE4 can increase levels of cAMP, leading to decreased expression of inflammatory factors and increased regulatory cytokines, making it a potential therapeutic target for chronic inflammatory conditions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Dermatology
Jia C. Gao, Albert G. Wu, Marissa N. Contento, Jacqueline M. Maher, Abigail Cline
Summary: Apremilast, a small molecule medication, has emerged as a promising option for the treatment of psoriasis and other inflammatory conditions. By inhibiting phosphodiesterase-4, apremilast reduces inflammatory cytokine production and has shown good efficacy and safety in clinical trials. It can be administered orally, providing a convenient and cost-effective therapeutic option.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2022)
Review
Dermatology
Mette Gyldenlove, Farzad Alinaghi, Claus Zachariae, Lone Skov, Alexander Egeberg
Summary: The evidence for combination therapy with apremilast and biologics is limited and mainly based on retrospective studies. Based on available data, apremilast may be an effective and safe add-on treatment to biologic therapy, but further clinical research is needed.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Review
Immunology
Yuanyuan Xu, Zhixuan Li, Shuwei Wu, Linghong Guo, Xian Jiang
Summary: This study compared the efficacy and safety of oral small-molecule drugs, including TYK2 and PDE4 inhibitors, in treating moderate-to-severe plaque psoriasis. It found that TYK2 inhibitors demonstrated satisfactory performance, surpassing apremilast at certain doses. More large-scale, long-term studies on novel TYK2 inhibitors are needed to validate these findings.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
John Miller, Abin P. Puravath, Ana-Maria Orbai
Summary: Ixekizumab treatment in PsA was associated with a statistically significant higher risk of injection site reactions versus placebo or adalimumab. Ixekizumab had statistically significantly fewer serious adverse events than adalimumab. Ixekizumab demonstrated efficacy for all PsA disease activity domains as well as for slowing radiographic disease progression.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Dermatology
Ulrich Mrowietz, Jonathan Barker, Curdin Conrad, Denis Jullien, Paolo Gisondi, Andrea Flower, Jyotsna Reddy, Maria Paris, Hernan Picard, Shauna Jardon, Matthias Augustin
Summary: This study evaluated the efficacy and safety of apremilast in patients with plaque psoriasis in special areas and found that it significantly improved patients' quality of life, affected skin condition, and reduced itching and skin discomfort/pain.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Immunology
Weize Gao, Zhan Wang, Wenshuai Li, Yongxin Li, Mingjun Liu
Summary: This review systematically demonstrates the research progress of psoriasis-related biomarkers and elaborates their related mechanisms in the pathological development of psoriasis and psoriatic arthritis. In addition, we summarize the development of biologic therapies for psoriasis and psoriatic arthritis in order to drive the broader discussion of psoriasis as an autoimmune-mediated inflammatory skin disease.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Chemistry, Medicinal
Ignatios Ikonomidis, George Pavlidis, Nikolaos Kadoglou, George Makavos, Konstantinos Katogiannis, Aikaterini Kountouri, John Thymis, Gavriella Kostelli, Irini Kapniari, Konstantinos Theodoropoulos, John Parissis, Pelagia Katsimbri, Evangelia Papadavid, Vaia Lambadiari
Summary: The phosphodiesterase 4 inhibitor apremilast has significant effects on endothelial glycocalyx, vascular, and myocardial function in the treatment of psoriasis. It restores glycocalyx integrity and confers greater improvement in vascular and myocardial function compared to anti-tumor necrosis factor-alpha or cyclosporine.
Article
Multidisciplinary Sciences
Hyung Jin Hahn, Sang Gyu Kwak, Dong-Kyu Kim, Jong-Yeup Kim
Summary: Research indicates that individuals with Behcet disease are more likely to develop psoriasis, with higher risk seen in male BD patients and older individuals. Additionally, Behcet disease patients are also more prone to developing psoriatic arthritis.
SCIENTIFIC REPORTS
(2021)
Article
Dermatology
D. Ioannides, N. Antonakopoulos, V Chasapi, C. Oikonomou, E. Tampouratzi, E. Lazaridou, D. Rigopoulos, O. Neofotistou, A. Drosos, G. Anastasiadis, E. Rovithi, C. Kalinou, E. Papadavid, P. Aronis, M. Papageorgiou, A. Protopapa, I Bassukas, I Lefaki, E. Zafiriou, K. Krasagakis, E. Pokas, Z. Anagnostopoulos, A. Kekki, M. Papakonstantis
Summary: This study evaluated the effectiveness and safety of apremilast in bio-naive patients with moderate psoriasis in real-world clinical settings. The results showed that apremilast is a safe and effective treatment for these patients, with improvements in quality of life.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Andrea Becciolini, Simone Parisi, Patrizia Del Medico, Antonella Farina, Elisa Visalli, Aldo Biagio Molica Colella, Federica Lumetti, Rosalba Caccavale, Palma Scolieri, Romina Andracco, Francesco Girelli, Elena Bravi, Matteo Colina, Alessandro Volpe, Aurora Ianniello, Maria Chiara Ditto, Valeria Nucera, Veronica Franchina, Ilaria Plate, Eleonora Di Donato, Giorgio Amato, Carlo Salvarani, Simone Bernardi, Gianluca Lucchini, Francesco De Lucia, Francesco Molica Colella, Daniele Santilli, Natalia Mansueto, Giulio Ferrero, Antonio Marchetta, Eugenio Arrigoni, Rosario Foti, Gilda Sandri, Vincenzo Bruzzese, Marino Paroli, Enrico Fusaro, Alarico Ariani
Summary: This retrospective observational study aimed to report the long-term disease activity index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and analyze the predictors of clinical response. The study found that almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. Baseline DAPSA was the only factor associated with achieving low disease activity or remission at both 6 and 12 months.
Article
Dermatology
Lisa A. Beck, Diamant Thaci, Mette Deleuran, Marjolein de Bruin-Weller, Zhen Chen, Faisal A. Khokhar, Meng Zhang, Zafer E. Ozturk, Brad Shumel
Summary: The study found that adults with moderate-to-severe AD treated with dupilumab for up to 3 years did not experience clinically significant changes in mean laboratory parameters, indicating that continuous long-term use of the treatment is supported without the need for laboratory monitoring.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Dermatology
D. Thaci, K. Eyerich, A. Pinter, M. Sebastian, K. Unnebrink, S. Rubant, D. A. Williams, P. Weisenseel
Summary: This study found that risankizumab was superior to FAEs in treating psoriasis, providing earlier and greater improvement in outcomes that persisted with continued treatment. Risankizumab also showed more favorable safety results with no new safety signals observed for either treatment arm.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Andrew Blauvelt, April W. Armstrong, Richard G. Langley, Kurt Gebauer, Diamant Thaci, Jerry Bagel, Lyn C. Guenther, Carle Paul, Bruce Randazzo, Susan Flavin, Ming-Chun Hsu, Yin You, Kristian Reich
Summary: In this study, guselkumab showed superior efficacy compared to secukinumab at week 48 in treating patients with moderate-to-severe plaque psoriasis, across various baseline characteristics. The largest differences in efficacy were observed in patients aged 65 and older, as well as in patients weighing over 100 kg.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Review
Dermatology
James Krueger, Lluis Puig, Diamant Thaci
Summary: Generalized pustular psoriasis (GPP) is a rare and severe skin disorder without approved specific therapies. Current treatment options are based on limited evidence and recent advances have identified potential targets for targeted therapy based on improved understanding of the disease mechanisms and gene mutations associated with GPP.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Article
Rheumatology
Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaci, Thilo Klopsch, Anja Plenske, Lisa K. Blindzellner, Pascal Klaus, Thomas Meng, Peter-Andreas Loeschmann
Summary: This study investigated the proportion of German patients with rheumatoid arthritis who achieved remission or low disease activity after 12 and 24 weeks of etanercept treatment. It found that a considerable proportion of patients attained their treatment targets after 12 weeks, and the proportion further increased with longer treatment duration.
RHEUMATOLOGY AND THERAPY
(2022)
Article
Dermatology
Diamant Thaci, Ron Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B. Kimball
Summary: The clinical and health-related quality of life responses observed during the first 16 weeks of BE SURE were sustained over 2 years of treatment, regardless of bimekizumab maintenance dosing. Switching from adalimumab to bimekizumab also resulted in sustained improvements up to Week 104. Bimekizumab had a good safety profile with no new safety signals.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaci, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen
Summary: Baricitinib demonstrated a consistent safety profile in the long-term treatment of atopic dermatitis patients, with no new safety signals identified. The incidence rates of major adverse cardiovascular events, deep vein thromboses/pulmonary emboli, malignancies, and serious infections were within the ranges observed in the background population of patients with AD.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Dermatology
Matthias Augustin, Andrea Bauer, Konstantin Ertner, Ralph von Kiedrowski, Florian Schenck, Jutta Ramaker-Brunke, Sophie Moeller, Anja Fait, Mike Bastian, Diamant Thaci
Summary: The PROLEAD study examined the effectiveness and safety of dupilumab in real-world clinical practice for patients with moderate-to-severe atopic dermatitis (AD). The results showed that dupilumab was more effective and well tolerated in a real-world setting compared to phase 3 clinical trials.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Mark G. Lebwohl, Joseph F. Merola, Katelyn Rowland, Megan Miller, Ya-Wen Yang, Jenny Yu, Yin You, Daphne Chan, Diamant Thaci, Richard G. Langley
Summary: This study evaluated the safety of guselkumab in 2891 patients with psoriasis who were treated for up to 5 years. The findings showed that guselkumab demonstrated favorable safety, consistent with previous reports. The safety event rates in guselkumab-treated patients were similar to those observed in the placebo group and remained consistent throughout long-term treatment.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Letter
Dermatology
Andrew Blauvelt, Diamant Thaci, Kim A. Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Daphne Chan, Jenny Yu, Ya-Wen Yang, Mark G. Lebwohl, Alice B. Gottlieb, Jeffrey Crowley, Peter Foley
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
A. D. Burden, Y. Okubo, M. Zheng, D. Thaci, P. van de Kerkhof, N. Hu, M. Quaresma, C. Thoma, S. E. Choon
Summary: Effisayil 1 was a study investigating the use of spesolimab in patients with a flare-up of generalized pustular psoriasis (GPP). The study found that patients receiving spesolimab showed rapid clearance of pustules and skin symptoms within 1 week. The effectiveness and safety of spesolimab were consistent across different patient demographic and clinical characteristics.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Dermatology
Nina Magnolo, Thomas Jaenicke, Athanasios Tsianakas, Wolfgang Czech, Diamant Thaci, Andreas Pinter, Delphine Kerob, Samir Salah, Thomas A. Luger
Summary: This study aimed to investigate the efficacy of skin care products containing emollients and a syndet with the ability to improve skin barrier and microbiome in moderate to severe AD patients. The results showed that patients using this product had significant improvements in itchiness and quality of life after 10 weeks, while using 23% less product compared to the control group.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Henning Olbrich, Christian D. Sadik, Ralf J. Ludwig, Diamant Thaci, Katharina Boch
Summary: Dupilumab, approved for atopic dermatitis and prurigo nodularis, has shown effectiveness in treating various dermatologic diseases including bullous autoimmune diseases, eczema, prurigo, and alopecia areata.
Correction
Rheumatology
Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaci, Thilo Klopsch, Anja Plenske, Lisa K. Blindzellner, Pascal Klaus, Thomas Meng, Peter-Andreas Loeschmann
RHEUMATOLOGY AND THERAPY
(2023)
Article
Oncology
Kim A. Papp, Mark G. Lebwohl, Diamant Thaci, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek C. Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Tina Pyo, Woori Ko
Summary: CT-P43 demonstrated equivalent efficacy to originator ustekinumab in adults with moderate to severe plaque psoriasis, with comparable pharmacokinetic, safety, and immunogenicity profiles.